EMA takes positive stance on Moderna COVID-19 vaccine for adolescents

By The Science Advisory Board staff writers

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has taken a positive position on marketing authorization for Moderna's COVID-19 vaccine for use in adolescents 12 years of age and older.

Following the EMA's nod, the European Commission will now consider authorizing the use of Moderna's vaccine in this population, Moderna said.

The company is now conducting a clinical study regarding use of its vaccine in children ages 6 months to less than 12 years, according to the firm.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?